| 2023/09/22 17:35:54 | |
|---|---|
| Price | |
| 779.50 EUR | |
| Difference | 1.23% (9.50) |
General attributes
| ISIN | US75886F1075 |
| Symbol | REGN |
| Exchange | Xetra |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 82,443 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 779.00 EUR |
| High | 781.50 EUR |
| Low | 776.50 EUR |
| Close (prev. day) | 770.00 EUR |
| VWAP | 779.50 EUR |
| Volume (pcs) | 37 |
| Trading volume | 28,841.50 |
| Number of trades | 5 |
| Last size | 1 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: REGENERON PHARMACEUTICALS INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/09/08 |
|
Global Equity Ratings |
|
| 2023/08/22 |
|
Global Equity Ratings |
|
| 2023/08/17 |
|
Global Equity Ratings |
|
| 2023/08/09 |
|
Global Equity Ratings |
|
| 2023/07/21 |
|
Global Equity Ratings |
|
| 2023/09/22 17:35:54 | |
|---|---|
| Price | |
| 779.50 EUR | |
| Difference | 1.23% (9.50) |
General attributes
| ISIN | US75886F1075 |
| Symbol | REGN |
| Exchange | Xetra |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 82,443 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 779.00 EUR |
| High | 781.50 EUR |
| Low | 776.50 EUR |
| Close (prev. day) | 770.00 EUR |
| VWAP | 779.50 EUR |
| Volume (pcs) | 37 |
| Trading volume | 28,841.50 |
| Number of trades | 5 |
| Last size | 1 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +11.04% | - | - |
| Perf (abs.) | +77.50 | - | - |
| Beta | 0.49 | 0.50 | 0.61 |
| Volatility | 26.72 | 27.27 | 27.27 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 774.60 EUR (10) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 765.93 EUR (14) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 709.08 EUR (18) |
| Ø price 250 days | Ø volume 250 days (pcs.) | - EUR (26) |
| YTD High | date | 785.00 EUR (2023/09/15) |
| YTD Low | date | 630.00 EUR (2023/01/10) |
| 52 Weeks High | date | 785.00 EUR (2023/09/15) |
| 52 Weeks Low | date | 630.00 EUR (2023/01/10) |
All listings for REGENERON PHARMACEUTICALS INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2023/09/22 | 17:35 | 779.50 EUR | 0.03 | 5 |
| Vienna Stock Exchange | 2023/09/22 | 17:32 | 778.00 EUR | 0.00 | 2 |
| Tradegate | 2023/09/22 | 22:26 | 775.50 EUR | 0.01 | 3 |
| Stuttgart | 2023/09/22 | 14:11 | 771.00 EUR | 0.00 | 4 |
| Nasdaq | 2023/09/22 | 22:00 | 824.84 USD | 383.64 | 14,816 |
| Munich | 2023/09/22 | 08:02 | 778.50 EUR | 0.00 | 1 |
| London Stock Exchange | 2023/09/06 | 17:18 | 825.24 USD | 0.05 | 1 |
| Hanover | 2023/09/22 | 08:36 | 772.50 EUR | 0.00 | 1 |
| Hamburg | 2023/09/22 | 08:36 | 772.50 EUR | 0.00 | 1 |
| Frankfurt | 2023/09/22 | 15:44 | 775.00 EUR | 0.00 | 2 |
| Duesseldorf | 2023/09/22 | 19:30 | 776.50 EUR | 0.00 | 5 |
| Berlin | 2023/09/22 | 08:02 | 770.50 EUR | 0.00 | 1 |
| BX Swiss | 2023/09/14 | 18:00 | 733.134 CHF | 0.00 | 1 |
Company Logo
Contact Details
| REGENERON PHARMACEUTICALS INC. |
| - - |
| 777 Old Saw Mill River Road - 10591-6707 Tarrytown |
| Telefon: +1-914-847-7000 |
| Fax: + |
| E-mail: - |
PDF Downloads
| Company report: REGENERON PHARMACEUTICALS INC. | |
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY. |
Members of Management Board
| George Yancopoulos | Chairman of Board of Directors |
| Bonnie Bassler | Member of Board of Directors |
| Craig Thompson | Member of Board of Directors |
| David Schenkein | Member of Board of Directors |
| Huda Zoghbi | Member of Board of Directors |
| Joseph Goldstein | Member of Board of Directors |
| Kathryn Guarini | Member of Board of Directors |
| Michael Brown | Member of Board of Directors |
| N. Coles | Member of Board of Directors |
| Arthur Ryan | Member of Board of Directors |
| Christine Poon | Member of Board of Directors |
| George Sing | Member of Board of Directors |
| Leonard Schleifer | Chairman of Managing Board |
| Alan Shuldiner | Member of Executive Committee |
| Andrew Murphy | Member of Executive Committee |
| Johnathan Lancaster | Member of Executive Committee |
| Kerry Reinertsen | Member of Executive Committee |
| Ned Braunstein | Member of Executive Committee |
| Neil Stahl | Member of Executive Committee |
| Beth Holly | Member of Executive Committee |
| Bob McCowan | Member of Executive Committee |
| Christopher Fenimore | Member of Executive Committee |
| Daniel van Plew | Member of Executive Committee |
| Gerald Underwood | Member of Executive Committee |
| Joseph LaRosa | Member of Executive Committee |